Potential Research Partners

Australia stands at the forefront of research in neuroscience and gene therapy, with a vibrant scientific community dedicated to unravelling the complexities of the brain and exploring innovative genetic interventions. Importantly, Australia’s regulatory framework is tailored to expedite progress while ensuring ethical standards.  SLC6A1 Kids will actively collaborate with research institutions, hospitals and universities to accelerate progress towards development of a gene therapy for SLC6A1 neurodevelopmental disorder and strategies for optimising treatment of the condition.  This page highlights some of the leading research institutions in Australia.

Children’s Medical Research Institute (CMRI)

Based in Sydney, New South Wales, the Children’s Medical Research Institute (CMRI) is a leading research institution dedicated to advancing child health through innovative medical research.  CMRI’s primary focus lies in the treatment of childhood genetic diseases, including epilepsy and neurodevelopmental disorders.  Researchers at CMRI are dedicated to understanding the genetic underpinnings of epilepsy and investigating therapeutic approaches, with a particular emphasis on gene therapy.

At the helm of CMRI’s Translational Vectorology Unit is Professor Leszek Lisowski, a globally renowned expert in viral vector gene therapies. Professor Lisowski is considering strategies for addressing SLC6A1 neurodevelopmental disorder through the application of viral vector gene addition techniques.

The Florey Institute of Neuroscience and Mental Health

The Florey Institute of Neuroscience and Mental Health, located in Melbourne, Victoria, is one of the largest brain research centers in the Southern Hemisphere. With a strong emphasis on translational research, the institute is dedicated to understanding the complexities of the brain and developing treatments for neurological disorders.  The Florey has made significant strides in researching the underlying mechanisms of epilepsy, including genetic factors and neural circuitry.  Their multidisciplinary teams work collaboratively to identify potential targets for gene therapies and explore innovative approaches for epilepsy treatment.

At the forefront of the Florey’s pioneering work is Professor Steven Petrou, a distinguished authority in neuroscience and a leading expert in genetic therapies.  His contributions have been instrumental in shaping the institute’s research endeavours.  Thanks to the generosity of Allan & Gill Gray Foundation, one of our parent-directors, Stuart Place, was able to secure a donation of A$620,000 to the Florey to support development of an antisense oligonucleotide treatment for SLC6A1 neurodevelopmental disorder.

Murdoch Children’s Research Institute

Located in Melbourne, Victoria, the Murdoch Children’s Research Institute drives progress in paediatric research, spanning a diverse range of medical disciplines.  With a particular emphasis on genomics, the institute has taken a proactive role in the study of genetic diseases, including conditions that impair speech and language in children.  Their stem cell research team is a global leader in pioneering the integration of stem cell technologies into clinical practice for the treatment of genetic disorders.  The institute’s research extends to improving epilepsy therapies, as well as investigating the roots of developmental regression in children with Autism Spectrum Disorder, which is defining feature of SLC6A1 neurodevelopmental disorder.

Queensland Brain Institute (QBI)

Situated in Brisbane, Queensland, the Queensland Brain Institute (QBI) is a leading center for neuroscience research in Australia.  While their core mission is focussed on uncovering the fundamental principles of brain function, QBI’s expertise extends to clinical applications.  Notably, QBI researchers have made significant strides in elucidating the mechanisms of epilepsy, including genetic factors.  Their pioneering focus on the development of brain organoids for precision testing and proficiency in neurogenetics positions them as key contributors to the understanding and evaluation of anti-epileptic medications.